Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

NCT ID: NCT02614872

Last Updated: 2021-09-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-26
• Study Completion Date: 2019-05-07

Brief Summary

This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung transplantation.

Detailed Description

There is clinical rationale to advocate the use of AAT(GLASSIA) therapy during episodes of lung inflammation, including acute and chronic rejection. AAT may provide more specifically targeted prevention of pathogenic inflammation, superior to that of general immunosuppressants, with little risk. AAT is the main inhibitor of Neutrophil elastase(NE) in the lower airways and patients with AAT deficiency have low concentrations of the protein in this region of the lung. This explains the proteinase/antiproteinase theory of the development of emphysema in deficient patients in which the amount of elastase released in the lung exceeds the amount of AAT. The net result is persistence of elastase activity leading to lung destruction and the pathological changes of emphysema. Administration of AAT will help to prevent further destruction of the lung architecture and reduce the inflammatory dysregulation that causes pulmonary dysfunction. It is expected that by attacking a specific and previously untreated key component of the pathophysiological cycle of BOS, AAT therapy would decrease the prevalence of BOS in lung transplant recipients and prolong life expectancy of these patients. This will be an open label study in order to ensure safety, in the frame of POC study.

Conditions

Transplantation, Lung Rejection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GLASSIA®

Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.

Group Type: EXPERIMENTAL

GLASSIA® and Institution standard of care (SOC)

Intervention Type: DRUG

Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)

Institution standard of care (SOC)

Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

GLASSIA® and Institution standard of care (SOC)

Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)

Intervention Type: DRUG

Other Intervention Names

GLASSIA and Institution standard of care (SOC)

Eligibility Criteria

Inclusion Criteria

1. Signed and dated informed consent.

2. Age ≥18 years.

3. Subject is planned to undergo first single or double lung transplant (including heart-lung transplant) as per standard implantation procedure.

Exclusion Criteria

1. Subject has immunoglobulin A (IgA) deficiency and known anti IgA antibodies.

2. Known history of OR positive serological evidence at the time of screening for hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Parvovirus B19 (PVB19) or human immunodeficiency virus (HIV) Type 1/2 infection

3. Subjects with a history of severe immediate hypersensitivity reactions, including allergies, anaphylaxis to plasma products or any human proteins of different source.

4. Pregnant or lactating women at entry to study and women of child bearing potential, who are unwilling to agree to continue to use acceptable methods of contraception throughout the study.

5. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the subject's ability to give informed consent or to comply with the requirements of the study protocol.

6. Alcohol abuse or history of alcohol abuse.

7. Illegal drugs.

8. Candidate for organ transplantation other than first lung or heart-lung transplantation

9. Clinically significant bronchial stenosis unresponsive to dilation and/or stenting

10. Participation in another interventional clinical trial within 30 days prior to baseline visit.

11. Inability to attend scheduled clinic visits and/or comply with the study protocol.

12. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kamada, Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mordechai Kramer, MD

Role: PRINCIPAL_INVESTIGATOR

Pulmonary institute, Rabin Medical Center, Israel.

Locations

Pulmonary Institute - Rabin Medical Center

Petah Tikva, , Israel

Countries

Israel

Other Identifiers

CT2-LUNG-IV-IL-014

Identifier Type: -

Identifier Source: org_study_id